Comparator: atorvastatin calcium

DRUG2 trials

Sponsors

Organon and Co, Merck Sharp & Dohme LLC

Conditions

HypercholesterolemiaMetabolic SyndromeMixed DyslipidemiaPrimary Hypercholesterolemia

Phase 3

Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)

CompletedNCT00409773

Organon and CoHypercholesterolemia, Metabolic Syndrome

Start: 2007-01-31End: 2008-07-31Updated: 2024-05-16

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

CompletedNCT00479388

Merck Sharp & Dohme LLCMixed Dyslipidemia, Primary Hypercholesterolemia

Start: 2007-07-31End: 2008-10-31Updated: 2015-03-10

Related Papers

Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.

2015-09-047 citations

Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.

2012-06-0114 citations

Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).

2011-06-1513 citations